Home
Resources
Publications
Bioresorbable Scaffolds for Coronary Artery Disease

Bioresorbable Scaffolds for Coronary Artery Disease

Ashwin Nathan, Taisei Kobayashi, Daniel M Kolansky, Robert L Wilensky, Jay Giri

Curr Cardiol Rep. 2017 Jan;19(1):5.

PMID: 28108898

Abstract:

Purpose of review:
The purpose of this review is to present an overview of the recent evidence regarding the use of bioresorbable scaffolds in percutaneous coronary intervention.
Recent findings:
Bioresorbable scaffolds represent a potentially unique engineering solution to the problems associated with metallic stents. The Absorb everolimus-eluting bioresorbable scaffold has been the most extensively tested of this class and is currently Food and Drug Administration-approved for use in the USA. While early studies suggested that it has comparable overall efficacy as compared to drug-eluting metallic stents, they also demonstrated a significantly increased risk of stent thrombosis. Bioresorbable scaffolds may be comparable to drug-eluting stents, though associated with an increased risk of stent thrombosis. They are a nascent technology with several competitive product designs in development and continued iterative technological improvements are expected over the next several years.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP159351696-A	Everolimus solution		159351-69-6	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: